Activate the full potential of your innovative science with a partner that helps you navigate your nephrology clinical trials with the expertise, capacity, and flexibility you need.

Developing strategies to successfully recruit and complete your study on time

Led by scientific experts, our team understands the nuances of your nephrology studies in both rare and non-rare indications. We have experience of the patients, clinicians, sites and points of contact, including dialysis centers, and we’re finely tuned to address their unique concerns and needs in designing studies and in developing strategies to successfully recruit and complete your study on time.

Drug development in nephrology indications is burgeoning and the competition for patients with rare kidney diseases is high. Overcoming this challenge requires a deep knowledge of the world of kidney disease and the finesse gained by years of experience designing, recruiting and completing studies in a broad range of rare diseases.

Patients in the kidney space often have comorbidities such as cardiovascular disease, diabetes and obesity, and with the comorbidities comes polypharmacy which can complicate exclusion criteria and other study design parameters. Our nephrology team works in collaboration with you to anticipate and minimize these issues.

We embed scientific and clinical expertise throughout your studies to ensure that your renally impaired patients have the specialized clinical oversight they need.

Our personalized partnership with you brings you global expertise and knowledge sharing, giving you the resources and support you need throughout your nephrology studies. Our experts guide you through feasibility assessment and start-up, which is a notable challenge in nephrology trials where patient enrollment is often slow. We then support you with constant monitoring and governance, through to regulatory filings and applications if needed.

By focusing on activating the right knowledge and expertise across our team, we give you more control over project outcomes, help you overcome boundaries, and achieve more.

Study experience

  • Acute kidney injury
  • Chronic kidney failure
    • Diabetic kidney disease
    • Autoimmune diseases, including lupus nephritis
    • Glomerulonephritis, including FSGS and C3GN
    • Polycystic kidney disease, autosomal dominant
  • End-stage renal disease
    • Hemodialysis
    • Peritoneal dialysis
    • Anemia of CKD, including iron supplements and erythropoiesis-stimulating agents
    • Renal bone disease and secondary hyperparathyroidism, including phosphate-binding agents, calcimimetics, and vitamin D analogs
    • Arterial calcification
    • Hemodialysis access, including catheter lock solutions
  • Hypertension, including Renal Artery Stenosis
  • Transplantation, including immunosuppressive therapy
  • Other orphan diseases, including:
    • Tuberous sclerosis
    • Fabry disease
    • Adrenal gland disorders
    • Scleroderma
    • Lysosomal storage diseases
Specialized clinical research solutions

Shared knowledge is power

We are fully invested in the outcomes of your trials, providing the resources and expertise when and how you need them and sharing therapeutic area expertise and knowledge to help you make the best decisions.

Gateway to the globe

Speak to a global expert

Ready for the next step in your drug development journey? Learn more about how our personalized solutions can help you enable better healthcare outcomes.

Schedule a 15 minute call
Leading a new way

The latest from Caidya

Explore our news and updates as we liberate the clinical research process.


Caidya Achieves Medidata Rave TSDV Accreditation, Enhancing Clinical Trial Efficiency and Data Integrity

Raleigh, N.C., June 12, 2024 – Caidya, a leading provider...


Caidya Expands Global Presence with the Establishment of Caidya Canada Limited and New Office in Toronto

Morrisville, NC, USA, April 1, 2024 - Caidya, a leading...

Gene Therapy Development 2024

13th June 2024 to 14th June 2024
London, UK
Skip to toolbar